# Bausch + Lomb's BL1332 Misses Primary Goal in Phase 2 Eye Pain Trial

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/61720
Published: 2026-11-19T22:31:44.000Z
Updated: 2026-11-19T22:31:44.000Z
Section: Business

> At 24 hours, the topical drug for pain after eye surgery showed no statistically significant improvement over vehicle, an inactive comparison formulation.

Bausch + Lomb Corporation's experimental BL1332, a topical TRPV1 antagonist for pain after eye surgery, failed to meet the primary endpoint of a Phase 2 clinical trial.

At 24 hours, BL1332 did not show a statistically significant improvement compared with vehicle. A vehicle is an inactive formulation used as the comparison in a trial.

BL1332 is being developed for post-surgical ocular pain. Bausch + Lomb trades under the ticker BLCO.


